Minoxidil (MNX), like several other vasoactive drugs, causes cardiovascular toxicity in dogs by undetermined mechanisms. We studied the mechanism of cardiovascular toxicity of MNX [an adenosine triphosphate (ATP)-sensitive potassium channel opener] by blocking its pharmacologic effects with glyburide (an ATP-sensitive potassium channel blocker) in groups of 5 female beagle dogs treated orally for 2 days with 1.0 mg/ kg/day of MNX alone or with glyburide given in 5 or 6 divided doses of 300 mg/kg at 2 hr before and after each dose of MNX and at 3-6-hr intervals thereafter. A third group of 5 dogs received glyburide alone in the same dosing regimen as in the combination group. Mean arterial pressure (MAP), heart rate (HR), the pharmacokinetics of MNX, and gross and microscopic changes in the heart were evaluated. Glyburide did not influence the pharmacokinetics of MNX but prevented or markedly attenuated the MNX-induced cardiovascular lesions (right atrial hemorrhagic lesions, subendocardial necrosis, or coronary arteritis) occurred in dogs whose MNX-induced hemodynamic effects were effectively blocked by glyburide. In conclusion, the cardiovascular toxicity of MNX in dogs is not caused by a direct toxic effect of MNX on the heart but apparently is related to the exaggerated pharmacologic/profound hemodynamic effects it elicits in the dog.
Ashcroft SJH and Ashcroft FM (1992). Minireview: The sulfonylurea receptor. Biochim. Biophys. Acta1175: 45-59.
2.
Bache RJ and Cobb FR (1977). Effect of maximal coronary vasodilatation on transmural myocardial perfusion during tachycardia in the awake dog. Circ. Res. 41: 468-653.
3.
Balazs T. (1981). Cardiotoxicity of adrenergic bronchodilator and vasodilating antihypertensive drugs. In: Cardiac Toxicology , T Balazs (ed). CRC Press, Boca Raton, Florida, pp. 61-72.
4.
Carlson RG and Feenstra ES (1977). Toxicologic studies with hypotensive agent minoxidil . Toxicol. Appl. Pharmacol. 39: 1-11.
5.
Christensen GC and Campeti FL (1959). Anatomic and functional studies of the coronary circulation in the dog and pig. Am. J. Vet. Res. 20: 18-26.
6.
Dogterom P., Zbinden G., and Reznik GK (1992). Cardiotoxicity of vasodilators and positive inotropic/ vasodialting drugs in dogs. An overview. Crit. Rev. Toxicol . 22: 203-241.
7.
DuCharme DW, Freyburger WA, Graham BE, and Carlson RG (1973). Pharmacologic properties of minoxidil : A new hypotensive agent. J. Pharmacol. Exp. Ther. 184: 662-670.
8.
Edwards G. and Weston AH (1990). Potassium channel openers and vascular smooth muscle relaxation. Pharmacol. Ther. 48: 237-258.
9.
Gans JH, Korson R., Cater MR, and Ackerly CC (1980). Effects of short term long term theobromine administration to male dogs. Toxicol. Appl. Pharmacol. 53: 481-496.
10.
Gopalakrishnan M., Janis RA, and Triggle DJ (1993). ATP-sensitive K+ channels: Pharmacological properties, regulation, and therapeutic potential. Drug Dev. Res. 28:95-127.
11.
Hayashi S., Horie M., and Okada Y. (1993). Ionic mechanism of minoxidil sulfate-induced shortening of action potential durations in guinea pig ventricular myocytes. J. Pharinacol. Exp. Ther. 265: 1527-1533.
12.
Herman EH, Balazs T., Ferrans VJ, and Young RSK (1981). Divergent effects of propranolol and furosemide pretreatment on acute cardiomyopathy induced by minoxidil in beagle dogs. Toxicology20: 155-164.
13.
Herman EH, Balazs T., Young R., Earl FLKrop S., and Ferrans VJ (1979). Acute cardiomyopathy induced by the vasodilating antihypertensive agent minoxidil. Toxicol. Appl. Pharmacol . 47: 493-504.
14.
Hof RP, Quast U., Cook NS, and Blarer S. (1988). Mechanism of action and systemic and regional hemodynamics of the potassium channel activator BRL 34915 and its enantiomers . Circ. Res. 62: 679-686.
Humphrey SJ and Zins GR (1984). Whole body and regional hemodynamic effects of minoxidil in the conscious dog. J. Cardiovasc. Pharmacol. 6: 979-988.
17.
Joris I. and Majno G. (1981). Medial changes in arterial spasm induced by L-norepinephrine . Am. J. Pathol. 105: 212-222.
18.
Kajioka S., Sakai T., Kitamura K., and Kuriyama H. (1990). Pinacidil opens the ATP-sensitive and Cadependent K channel in smooth muscle cells of the rat and rabbit portal veins. Eur. J. Pharmacol. 183: 268-269.
19.
Kass RS and Freeman LC (1993). Potassium channels in the heart, cellular, molecular, and clinical implications. Trends Cardiovasc. Med. 3: 149-159.
20.
Kerns WD, Arena E., Macia RA, Bugelski PJ, Matthews WD, and Morgan DG (1989). Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat. Toxicol. Pathol. 17: 203-213.
21.
Kobori K., Suzuki K., Yoshida Y., and Ooneda G. (1979). Light and electron microscopic studies on rat arterial lesions induced by experimental arterial contraction. Virchows Arch. A Pathol. Anat. Histol. 385: 29-39.
22.
McCall JM, Aiken JW, Chidester CG, DuCharme DW, and Wendling MG (1983). Pyrimidine and triazine 3-oxide sulfates: A new family of vasodilators. J. Med. Chem . 26: 1791-1793.
23.
Meisheri KD , Cipkus LA, and Taylor CJ (1988). Mechanism of action of minoxidil sulfate-induced vasodilation: A role for increased K+ permeability . J. Pharmacol. Exp. Ther. 245: 751-760.
24.
Meisheri KD , Johnson GA, and Puddington L.(1993). Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem. Pharmacol. 45: 271-279.
25.
Meisheri KD , Khan SJ, and Martin JL (1993). Vascular pharmacology of ATP-sensitive K+ channels: Interactions between glyburide and K+ channel openers. J. Vasc. Res. 30: 2-12.
26.
Meisheri KD , Oleynek JJ, and Puddington L. (1991). Role of protein sulfation in vasodilation induced by minoxidil sulfate, a K+ channel opener. J. Pharmacol. Exp. Ther. 258: 1091-1097.
27.
Meisheri KD , Swirtz MA, Purohit SS, Cipkus-Dubray LA, Khan SA, and Oleynek JJ (1991). Characterization of K+ channel-dependent as well as independent components of pinacidil-induced vasodilation . J. Pharmacol. Exp. Ther . 256: 492-499.
28.
Mesfin GM (1990). Spontaneous epicardial fibrous fronds on the atria of beagle dogs. Vet. Pathol. 27: 458-461.
29.
Mesfin GM, Piper RC, DuCharme DW, Carlson RG, Humphrey SJ, and Zins GR (1989). Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol. Pathol. 17: 164-181.
30.
Nakaya H., Takeda Y., Tohse N., and Kanno M. (1991). Effects of ATP-sensitive K+ channel blockers on the action potential shortening in hypoxic and ischemic myocardium. Br. J. Pharmacol. 103: 1019-1026.
31.
Nemes Z., Dietz R., Mann JFE, Lüth JB, and Gross F. (1980). Vasoconstriction and increased blood pressure in the development of accelerated vascular disease. Virchows Arch. A Pathol. Anat. Histol. 386: 161-174.
32.
Newgreen DT , Bray KM, McHarg AD, Weston AH, Duty S., Brown BS, Kay PB, Edwards G., Longmore J., and Southerton JS (1990). The action of diazoxide and minoxidil sulphate on rat blood vessels: A comparison with cromakalim. Br. J. Pharmacol. 100: 605-613.
33.
Quast U. (1992). Potassium channel openers: Pharmacological and clinical aspects-review. Fundam. Clin. Pharmacol. 6: 279-293.
34.
Quast U. and Cook NS (1989). In vitro and in vivo comparisons of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. J. Pharmacol. Exp. Ther. 250: 261-271.
35.
Richer C., Pratz J., Mulder P., Mondot S., Giudicelli JF, and Cavero I. (1990). Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties . Life Sci. 47: 1693-1703.
36.
Stryker JA, Lee KJ, and Abt AB (1980). The effects of x-radiation on the canine heart . Radiat. Res. 82: 200-210.
37.
Van Vleet JF , Herman EH, and Ferrans JV (1984). Cardiac morphologic alterations in acute minoxidil cardiotoxicity in miniature swine. Exp. Mol. Pathol. 41: 10-25.
38.
Wickenden AD , Grimwood S., Grant TL, and Todd MH (1991). Comparison of the effects of the K+channel openers cromakalim and minoxidil sulphate on vascular smooth muscle. Br. J. Pharmacol. 103: 1148-1152.
39.
Winquist RJ , Heaney LA, Wallace AA, Baskin EP, Stein RB, Garcia ML, and Kaczorowski GJ (1989). Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle. J. Pharmacol. Exp. Ther. 248: 149-156.
